23083-Lung Cancer-NA-1648

Lung Cancer

A Phase III, Two-Arm, Parallel, Randomized, Multi-Center,Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) (eVOLVE-Lung02) (D798AC00001)

  • Details

ClinicalTrials.gov ID: NCT05984277
Diagnosis Type: NA
USOR Number:

  • Address


,
P:

Search by practice name, trial titles, indicators and specific disease types.